Method for treating myeloma utilizing an expression enhancer for HM1.24 antigen
US8287863B2 · kind B2 · utility
0Cited by
8References
7Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 13, 2006 |
| Grant date | Oct 16, 2012 |
| Priority date | — |
| Expiry date | May 11, 2026 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2039/505
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
An enhancer of expression, in the myeloma cell, of HM1.24 antigen, said enhancer comprising interferon-α or interferon-γ, or IRF-2 protein as an active ingredient. Interferon-α or interferon-γ is expected to enhance the expression of HM1.24 antigen by activating the promoter of a gene encoding HM1.24 antigen.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.